Calorie Restriction Impairs Anti-Tumor Immune Responses in an Immunogenic Preclinical Cancer Model

被引:1
|
作者
Dung, Nguyen Tien [1 ,2 ]
Susukida, Takeshi [2 ]
Ucche, Sisca [2 ]
He, Ka [2 ]
Sasaki, So-ichiro [2 ]
Hayashi, Ryuji [1 ]
Hayakawa, Yoshihiro [2 ]
机构
[1] Univ Toyama, Toyama Univ Hosp, Dept Med Oncol, Toyama 9300194, Japan
[2] Univ Toyama, Inst Nat Med, Sect Host Def, Toyama 9300194, Japan
关键词
calorie restriction; host immune response; CD8(+) T cell; immune checkpoint inhibitor; OBESITY; PREVENTION; MECHANISMS; DIET; INFLAMMATION; ACTIVATION; OVERWEIGHT; NUTRITION; EXERCISE; BLOCKADE;
D O I
10.3390/nu15163638
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
(1) Background: Although the important role of dietary energy intake in regulating both cancer progression and host immunity has been widely recognized, it remains unclear whether dietary calorie restriction (CR) has any impact on anti-tumor immune responses. (2) Methods: Using an immunogenic B16 melanoma cell expressing ovalbumin (B16-OVA), we examined the effect of the CR diet on B16-OVA tumor growth and host immune responses. To further test whether the CR diet affects the efficacy of cancer immunotherapy, we examined the effect of CR against anti-PD-1 monoclonal antibody (anti-PD-1 Ab) treatment. (3) Results: The CR diet significantly slowed down the tumor growth of B16-OVA without affecting both CD4(+) and CD8(+) T cell infiltration into the tumor. Although in vivo depletion of CD8(+) T cells facilitated B16-OVA tumor growth in the control diet group, there was no significant change in the tumor growth in the CR diet group with or without CD8(+) T cell-depletion. Anti-PD-1 Ab treatment lost its efficacy to suppress tumor growth along with the activation and metabolic shift of CD8(+) T cells under CR condition. (4) Conclusions: Our present results suggest that a physical condition restricted in energy intake in cancer patients may impair CD8(+) T cell immune surveillance and the efficacy of immunotherapy.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] SUMOylation inhibitors activate anti-tumor immunity by reshaping the immune microenvironment in a preclinical model of hepatocellular carcinoma
    Zengbin Wang
    Banglun Pan
    Lili Su
    Huahui Yu
    Xiaoxuan Wu
    Yuxin Yao
    Xiaoxia Zhang
    Jiacheng Qiu
    Nanhong Tang
    Cellular Oncology, 2024, 47 : 513 - 532
  • [42] Personalization of oncolytic virus therapy: Heterogenous anti-tumor responses in preclinical prostate and bladder cancer models
    Janssen, Thijs J.
    van der Horst, Geertje
    van der Merbel, Arjanneke F.
    van der Mark, Maaike
    Lamfers, Martine L.
    van den Hoogen, Bernadette G.
    van der Burg, Sjoerd S.
    Mustafa, Dana A.
    Mehra, Niven
    Aalders, Tilly
    van Montfoort, Nadine
    Schalken, Jack
    Hoeben, Rob C.
    van der Pluijm, Gabri
    CANCER RESEARCH, 2023, 83 (07)
  • [43] Photodynamic therapy modulates extracellular matrix and induces anti-tumor immune responses in an orthotopic pancreatic cancer model.
    Saad, Mohammad A.
    Morala, Jimena Nicolas
    Mai, Zhiming
    Hasan, Tayyaba
    CANCER IMMUNOLOGY RESEARCH, 2022, 10 (12)
  • [44] The immune system as anti-tumor sentinel: Molecular requirements for an anti-tumor immune response
    Markiewicz, MA
    Gajewski, TF
    CRITICAL REVIEWS IN ONCOGENESIS, 1999, 10 (03): : 247 - 260
  • [45] Tumor exosomal microRNAs thwarting anti-tumor immune responses in nasopharyngeal carcinomas
    Kapetanakis, Nikiforos-Ioannis
    Baloche, Valentin
    Busson, Pierre
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (07)
  • [46] Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model
    Jyothi Thyagabhavan Mony
    Lixin Zhang
    Tianzhou Ma
    Shannon Grabosch
    Tejas S. Tirodkar
    Joan Brozick
    George Tseng
    Esther Elishaev
    Robert P. Edwards
    Xin Huang
    Anda M. Vlad
    Cancer Immunology, Immunotherapy, 2015, 64 : 1095 - 1108
  • [47] Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model
    Mony, Jyothi Thyagabhavan
    Zhang, Lixin
    Ma, Tianzhou
    Grabosch, Shannon
    Tirodkar, Tejas S.
    Brozick, Joan
    Tseng, George
    Elishaev, Esther
    Edwards, Robert P.
    Huang, Xin
    Vlad, Anda M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (09) : 1095 - 1108
  • [48] Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model
    Veinalde, Ruta
    Pidelaserra-Marti, Gemma
    Moulin, Coline
    Tan, Chin Leng
    Schaefer, Theresa E.
    Kang, Na
    Ball, Claudia R.
    Leichsenring, Jonas
    Stenzinger, Albrecht
    Kaderali, Lars
    Jaeger, Dirk
    Ungerechts, Guy
    Engeland, Christine E.
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [49] Cancer stem cell antigen nanodisc cocktail elicits anti-tumor immune responses in melanoma
    Aikins, Marisa E.
    Qin, You
    Dobson, Hannah E.
    Najafabadi, Alireza Hassani
    Lyu, Kexing
    Xu, Yao
    Xin, Ying
    Schwendeman, Anna
    Wicha, Max S.
    Chang, Alfred E.
    Li, Qiao
    Moon, James J.
    JOURNAL OF CONTROLLED RELEASE, 2022, 351 : 872 - 882
  • [50] CCR2 Blockade Enhances Anti-tumor Immune Responses in Patients with Pancreatic Cancer
    Sanford, D.
    Belt, B.
    Panni, R.
    Nywening, T.
    Wang-Gillam, A.
    Goedegebuure, P.
    Linehan, D.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S39 - S39